Principia Biopharma, a US-based biopharmaceutical company focused on autoimmune diseases and cancer, has received $12.5m in its second trache of a series A round from a consortium including drugs company GlaxoSmithKline’s (GSK) corporate venturing unit. Alongside GSK’s SR One, which has partner Simeon George on Principia’s board, in the round were venture capital firms New…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
